Andy Crockett, KalVista Pharmaceuticals CEO
KalVista reports PhIII success of on-demand, oral hereditary angioedema drug as it seeks to challenge injectables
KalVista Pharmaceuticals’ oral medicine for hereditary angioedema helped relieve attack symptoms associated with the disease substantially faster than placebo in a late-stage study, setting the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
